Actively Recruiting

Phase 4
Age: 18Years - 64Years
All Genders
ID04400266

Buspirone and Melatonin for Depression Following Traumatic Brain Injury

Led by Massachusetts General Hospital · Updated on 2026-05-06

10

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the combination of buspirone and melatonin (B+MEL) to treat depression that occurs after a traumatic brain injury (TBI). Post-TBI depression often includes symptoms like anxiety, aggression, fatigue, and irritability and may differ from general clinical depression. This study aims to evaluate changes in depressive and cognitive symptoms and explore brain activity changes using functional magnetic resonance imaging (fMRI). Participants will receive buspirone 15 mg once daily and melatonin 3 mg once nightly. This trial investigates how this combination affects depression and cognitive function in people who have experienced mild to moderate TBI at least three months prior. The study will also use brain scans to observe changes in resting state functional connectivity related to treatment. During the study, participants will be assessed for changes in depressive symptoms using the HAM-D scale and cognitive abilities such as verbal memory, executive function, and processing speed. Brain imaging will be conducted before and after treatment to examine brain network activity. The total participation involves regular appointments over a 6-week treatment period, during which symptoms and brain function will be closely monitored.

CONDITIONS

Brief Title

Buspirone and Melatonin for Depression Following Traumatic Brain Injury

Who Can Participate

Age: 18Years - 64Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with mild or moderate traumatic brain injury at least 3 months prior to study entry
  • Age between 18 and 64 years
  • Glasgow Coma Scale score between 9 and 15 within 4 hours after injury, or loss of consciousness between more than 1 minute and 24 hours, or post-traumatic amnesia less than 7 days
  • English-speaking
  • Current diagnosis of major depressive episode according to DSM-5
  • HAM-D-21 score of 18 or higher
  • Considered appropriate for buspirone and melatonin treatment by their clinician and willing to start treatment
Not Eligible

You will not qualify if you...

  • History of neurological disorders like stroke, epilepsy, multiple sclerosis, HIV, or neurodegenerative diseases
  • Severe traumatic brain injury (Glasgow Coma Scale 8 or less, loss of consciousness over 24 hours, or post-traumatic amnesia over 7 days)
  • Inability to attend regular appointments
  • Imminent risk of suicide as determined by clinician
  • Lifetime history of schizophrenia or primary psychotic disorders
  • History of bipolar disorder
  • Alcohol or substance dependence in the past 3 months
  • Pregnancy or breastfeeding
  • Use of buspirone, psychostimulants, or modafinil/armodafinil
  • Current or recent antidepressant use within past 4 weeks
  • Prior intolerance to buspirone or melatonin
  • Conditions preventing MRI participation such as metal implants or claustrophobia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 6 weeks

Participants receive buspirone 15mg once daily and melatonin 3mg once nightly to treat depression following traumatic brain injury.

Weekly visits for up to 6 weeks

Follow-up

Duration - Post-treatment assessments immediately following the 6-week treatment period

Participants are assessed for changes in depressive symptoms, cognitive function, and brain connectivity after treatment.

1 visit (in-person)

Trial Site Locations

Total: 2 locations

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02144

Actively Recruiting

2

Massachusetts General Hospital Home Base Program

Charlestown, Massachusetts, United States, 02129

Actively Recruiting

Loading map...

Research Team

K

Kaloyan Tanev

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

The Effects of Citalopram on the Brain's Response to Emotion...

Emotional Processing

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here